F-star Therapeutics, Inc. (NASDAQ:FSTX) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of F-star Therapeutics, Inc. (NASDAQ:FSTXGet Rating) have been assigned an average rating of “Buy” from the seven analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $29.20.

Several research analysts have recently issued reports on FSTX shares. Zacks Investment Research raised F-star Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, February 8th. HC Wainwright started coverage on shares of F-star Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $35.00 target price for the company.

Shares of FSTX stock traded down $0.03 during trading hours on Friday, reaching $2.53. The stock had a trading volume of 48,586 shares, compared to its average volume of 132,594. The company has a debt-to-equity ratio of 0.14, a current ratio of 6.11 and a quick ratio of 6.11. F-star Therapeutics has a twelve month low of $2.07 and a twelve month high of $9.71. The firm has a 50-day simple moving average of $3.14 and a 200-day simple moving average of $4.10. The firm has a market capitalization of $54.54 million, a PE ratio of -1.64 and a beta of 1.86.

F-star Therapeutics (NASDAQ:FSTXGet Rating) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.06. The business had revenue of $2.55 million for the quarter, compared to analyst estimates of $2.30 million. On average, equities analysts anticipate that F-star Therapeutics will post -2.39 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Morgan Stanley lifted its holdings in F-star Therapeutics by 65.0% in the 2nd quarter. Morgan Stanley now owns 7,868 shares of the company’s stock valued at $68,000 after acquiring an additional 3,100 shares during the last quarter. Truist Financial Corp lifted its position in shares of F-star Therapeutics by 71.6% in the 3rd quarter. Truist Financial Corp now owns 79,092 shares of the company’s stock valued at $579,000 after acquiring an additional 33,000 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of F-star Therapeutics by 1.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 177,286 shares of the company’s stock valued at $1,296,000 after acquiring an additional 2,513 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of F-star Therapeutics by 11.6% in the 3rd quarter. Geode Capital Management LLC now owns 145,431 shares of the company’s stock valued at $1,064,000 after acquiring an additional 15,152 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of F-star Therapeutics in the 3rd quarter valued at approximately $114,000. 51.67% of the stock is currently owned by institutional investors.

About F-star Therapeutics (Get Rating)

F-star Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.

Recommended Stories

Analyst Recommendations for F-star Therapeutics (NASDAQ:FSTX)

Receive News & Ratings for F-star Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for F-star Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.